explore -WSS

explore

author：focus 2025-09-28 00:52:49 - browse：7923

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

focus

WSS

Why a market frenzy over new weight loss drugs defies logic

Roche drug slashes death risk in early

Health tech investors get more selective as pandemic boom fades

Roivant's CEO is a star, but biotech's black hole persists

Is there really a nursing shortage in the U.S.?

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

entertainment

explore

hotspot

Guidelines to prevent youth baseball injuries need more muscle

STAT Summit: The economic case for universal basic health care

How one medical school became remarkably diverse

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Psychedelics group wrestles with new pharma identity

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Dobbs anniversary: the lost opportunity of abortion as health care

UnitedHealth, Optum discontinue NaviHealth name

What does generative AI mean for health care? We asked experts

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

focus

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

STAT Readout: Friday, Oct. 20 biotech updates

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Readout LOUD podcast: Live from the 2023 STAT Summit

STAT Summit: Meghan O’Rourke on making chronic illness visible

Health tech investors get more selective as pandemic boom fades

focus

hotspot

focus

knowledge